Medicinal use of cannabis in the treatment of epilepsy
DOI:
https://doi.org/10.33448/rsd-v11i8.30471Keywords:
Epilepsy; Pharmacology; Cannabis Sativa; Treatment; Health teaching.Abstract
Epilepsy is a neurological disease, characterized by excessive neuronal activity, the seizures. Studies show that the incidence of symptoms is higher in the first year of life, and the approximate number of patients affected in the world is 70 million people. Objective: The objective of this present work is to investigate the medicinal use of cannabis, as well as to analyze its safety and efficacy in the treatment of epilepsy. Methodology: To make this possible, a systematic review was carried out in such databases: ScienceDirect, Virtual Health Library – VHL and Pubmed, using the descriptors cannabis and epilepsy, cannabis and pharmacology, cannabis treatment, epilepsy. Results: Drugs that are used as a form of treatment are effective in about 70% of cases, with the remaining 30% presenting a refractory form to treatment. These circumstances generate fervor in the development of effective therapeutic solutions in the treatment of these refractory cases, in this way, cannabis comes to gain space, when it has several therapeutic functions, such as reducing the frequency of seizures, which is of great value for such patients. Conclusion: From the data collection, the conclusion is that the use of cannabis has a promising effect in the treatment of epilepsy, when compared to conventional pharmacotherapy, even with some side effects that are somewhat acceptable. It is of considerable importance to emphasize that because it is an extract that originates from a plant seen as a psychoactive drug, its label becomes valuable for scientific advancement, requiring further analysis and future studies.
References
Bragatti, J. A. et al. (2013). Protocolos Clínicos e Diretrizes Terapêuticas. Portal Aquivos. https://portalarquivos2.saude.gov.br/images/pdf/2014/abril/02/pcdt-epilepsia-livro-2013.pdf
Carvalho, C. R. et al. (2017). Canabinoides e Epilepsia: potencial terapêutico do canabidiol. Vittalle Revista de Ciências da Saúde. 1(9), 54-63. https://periodicos.furg.br/vittalle/article/view/6292/4740.
Correa, T. D. (2016). Utilização dos Canabinóides no Tratamento de Epilepsia em Pacientes Refratários. Brasília. https://repositorio.uniceub.br/jspui/bitstream/235/11061/1/21103443.pdf .
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Narbbout, R., Schffer, I. E., Thiele, E. A. & Wright, S. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal Of Medicine. 376(21), 2011-20. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1611618.
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D. & Vanlandingham, K. E. (2018). Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. New England Journal Of Medicine, [s.l.], 378(20), 1888-97. Massachusetts Medical Society. http://dx.doi.org/10.1056/nejmoa1714631.
Devinsky, O., Verducci, C., Thiele, E. A., Laux, L. C., Patel, A. D., Filloux, F., Szaflarski, J. P., Wilfong, A., Clark, G. D. & Park, Y. D. (2018). Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy & Behavior, [s.l.], 86, 131-37. Elsevier BV. http://dx.doi.org/10.1016/j.yebeh.2018.05.013.
Gaston, T. E., Bebin, E. M., Cutter, G. R. & Liu, Y., Szaflarski, J. P. (2017). Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, [s.l.], 58(9), 1586-92. Wiley. http://dx.doi.org/10.1111/epi.13852.
Gil, A. C. (2010) Como Elaborar Projetos. 5ª ed. São Paulo: Atlas.
Gontijo, É. C. et al. (2016). Canabidiol e suas Aplicações Terapêuticas. Refacer, 5(1). http://periodicos.unievangelica.edu.br/index.php/refacer/article/view/3360/2360.
Hess, E. J., Moody, K. A., Geffrey, A. L., Pollack, S. F., Skirvin, L. A., Bruno, P. L., Paolini, J. L. & Thiele, E. A. (2016) Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia, [s.l.], 57(10), 1617-24. Wiley. http://dx.doi.org/10.1111/epi.13499.
Laux, L. C., Bebin, E. M., Checketts, D., Chez, M., Flamini, R., Marsh, E. D., Miller, I., Nichol, K., Park, Y. & Segal, E. (2019) Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy Research, [s.l.], 154, 13-20. Elsevier BV. http://dx.doi.org/10.1016/j.eplepsyres.2019.03.015.
Marconi, M. A. & Lakatos, E. M. (2009) Metodologia do Trabalho Científico: procedimentos básicos, pesquisa bibliográfica, projeto e relatório, publicações e trabalhos científicos. 7ª ed. São Paulo: Atlas.
Matos, R. L. A. et al. (2017) O Uso do Canabidiol no Tratamento da Epilepsia. Revista Virtual de Química, 9(2), 786-814. http://rvq.sbq.org.br/imagebank/pdf/v9n2a24.pdf
Medeiros, J. B. (2004) Redação Científica: a prática de fichamentos, resumos, resenhas. 6ª ed. São Paulo: Atlas.
Mitelpunkt. A., Kramer, U., Kedem, M. H., Fink, E. Z., Orbach, R., Chernuha, V., Fattal-Valevski, A., Deutsch, L., Heffetz, D. & Sacks, H. (2019) The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Epilepsy & Behavior, [s.l.], 98, 233-37. Elsevier BV. http://dx.doi.org/10.1016/j.yebeh.2019.07.007.
Organization, W. H. (2006) Neurological Disorders: Public Health Challenges. https://www.who.int/mental_health/publications/neurological_disorders_ph_challenges/en/
Organization, W. H. (2019) Epilepsy: a public health imperative. https://www.who.int/mental_health/neurology/epilepsy/report_2019/en/
Pereira, F. A. et al. (2018) Efeitos do canabidiol na frequência das crises epilépticas. Revista Brasileira de Neurologia e Psiquiatria, 1(22), 86-100. https://www.revneuropsiq.com.br/rbnp/article/view/349/135
Rosenberg, E. C., Louik, J., Conway, E., Devinsky, O. & Friedman, D. (2017) Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol. Epilepsia, [s.l.], 58(8), 96-100. Wiley. http://dx.doi.org/10.1111/epi.13815.
Sampaio, R. & Mancini, M. (2007). Estudos de revisão sistemática: um guia para síntese. Revista Brasileira
de Fisioterapia, 11(1),. 83–89.
Santos, A. S. (2015). O uso de Canabinóides no Tratamento de Epilepsia. Realeza. https://rd.uffs.edu.br/handle/prefix/2641
Santos, A. B., Scherf, J. R. & Mendes, R. C. (2019) Eficácia do Canabidiol no Tratamento de Convulsões e Doenças do Sistema Nervoso Central. Acta Brasiliensis, 1(3), 30-34. revistas.ufcg.edu.br/ActaBra/index.php/actabra/article/view/131/60
Seibel, D. R. & Limberger, J. B. (2017). Uso de Canabidiol no Tratamento de Síndromes Epilépticas Resistentes a Terapia Convencional. Disciplinarum Scientia, 18(2), 363-380. https://periodicos.ufn.edu.br/index.php/disciplinarumS/article/view/2360
Silva, S. A. & Saraiva, A. L. L. (2019). Uso do Canabidiol em Portadores de Crises Convulsivas Refratárias no Brasil. Revista Uningá, 1(56), 1-16, http://revista.uninga.br/index.php/uninga/article/view/2131/1877
Szaflarski, J. P., Bebin, E. M.., Cutter, G., Dewolfe, J., Dure, L. S., Gaston, T. E., Kankirawatana, P., Liu, Y., Singh, R. & Standaert, D. G. (2018). Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study. Epilepsy & Behavior, [s.l.], 87, 131-36. Elsevier BV. http://dx.doi.org/10.1016/j.yebeh.2018.07.020
Tzadok, M., Uliel-Siboni, S., Linder, I., Kramer, U., Epstein, O., Menascu, S., Nissenkorn, A., Yosef, O. B., Hyman, E., Granot, D. (2016). CBD-enriched medical cannabis for intractable pediatric epilepsy. Seizure, [s.l.], 35, 41-44. Elsevier BV. http://dx.doi.org/10.1016/j.seizure.2016.01.004.
Yochimura, D. (2019) Perfil terapêutico do canabidiol em epilepsias. Uberlândia. http://repositorio.ufu.br/bitstream/123456789/26558/4/PerfilTerapeuticoCanabidiol.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Ana Karolaynne Soares da Silva; Tibério Cesar Lima de Vasconcelos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
